Early-phase trials of NK cell therapies, such as the HLA-mismatched CD19-targeting CAR-NK therapy (NCT03056339), reported no GvHD and demonstrated a favorable safety profile with no CRS or neurotoxicity [83]. This evidence concerns the gene CD19 and graft versus host disease.